BOC-GROUP
15.1.2020 15:29:10 CET | Business Wire | Press release
BOC Group , a global leader in enterprise business process analysis software (EBPA), and TIM Solutions , a leading provider of business process management (BPM) software for low-code human workflow automation, announced their strategic partnership today, focused on delivering accelerated digitalization of Business Process Automation at the enterprise level.
Both BOC Group and TIM have experienced that rapid automation of an existing manual process is the key first step in successful delivery of process automation. Once the automation is up-and-running, process analysis and design ensure that the process is quickly optimized further to reach cost reduction efficiencies of up-to 80%. What’s more, this approach delivers on all key targets of automation – reduction of redundant process activities, digitalization of manual tasks, and the overall improvement of customer experience. By combining TIM’s process automation with ADONIS’ process design and analysis capabilities, organizations can expect both a shorter time-to-value when automating processes, and a higher value-add delivered by the optimally designed automation.
The past months of collaboration between TIM and BOC Group have culminated today in a meeting of both management teams at BOC Group’s headquarters in Vienna, Austria, where the release of the ADONIS Process Automation module on the BOC Marketplace was announced. Customers of both partners can now benefit from this native integration that combines the intuitive process design, analysis and simulation of ADONIS with the seamless deployment, automation and monitoring of business processes in TIM’s process automation platform.
“Our customers seek to use low-code process automation as a key step in their digital journey. TIM is uniquely positioned as a simple, powerful and cost-effective automation platform that allows our customers to turn their process designs into automated workflows” mentioned Dr. Harald Kühn, BOC Group Board member. “We are excited about ADONIS Process Automation, powered by TIM, going live today on the BOC Marketplace” added Dr. Kühn.
“Having an optimal process design is a key success factor in rolling-out an automated human workflow. We are certain that the process analysis and design capabilities of ADONIS will be greatly beneficial when designing and optimizing automated workflows.” said TIM Solutions CEO, Mr. Hermann Filss “We are excited to be partnering with BOC Group as we look to directly profit from their global client footprint and rapidly spread the use of TIM around the world,” added Mr. Filss.
Both vendors have kicked-off campaigns to roll-out the integration as they look to capture a very active process automation market with their unique combined offering. Interested parties are welcome to schedule a Proof of Concept through the BOC Marketplace .
About BOC Group
BOC is a global leader in Enterprise Modelling Software across the Enterprise Business Process Analysis (EBPA), Governance Risk and Compliance (GRC) and Enterprise Architecture (EA) domains. Enabling customers to successfully and continuously re-design their digital enterprise to ensure business success at every level of the organization.
ADONIS customers include:
- Allianz
- Comcast
- Emerson
- Hilti
- Telefonica
BOC delivers products and services globally to over 1,000 companies supported by over 90 partners around the globe.
About TIM Solutions
TIM Solutions is focused on developing a simple method for automating and managing human workflows. They provide comprehensive solutions and consulting to their customers in the field Business Process Automation and Business Process Management.
TIM customers include:
- BMW AG
- Deutsche Bahn AG
- ManpowerGroup
- E.ON SE
- Tata Consultancy Services
TIM BPM Suite is used by more than 310 companies in 56 countries around the globe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005507/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom